Notice of Proposed Sale · 144
TEVA PHARMACEUTICAL INDUSTRIES LTD
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- TEVA PHARMACEUTICAL INDUSTRIES LTD
- Issuer CIK
- 0000818686
- SEC file number
- 001-16174
- Phone
- 972 (3) 914-8213
- Person for whose account securities are to be sold
- Hughes Eric A
- Relationships to issuer
- Executive VP Global R&D and Chief Med Officer
- Street
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Street (continued)
- 124 DVORA HANEVI'A ST.
- City
- TEL AVIV
- State / country code
- L3
- Postal code
- 6944020
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Ordinary Shares | 25,578 | 892,050.65 | 1,165,296,084 | 08/03/2026 | NYSE | Citigroup Global Markets, Inc |
Broker / market maker — proposed row 1, entry 1
- Name
- Citigroup Global Markets, Inc
- Street
- 390 Greenwich St
- City
- New York
- State / country code
- NY
- Postal code
- 10013
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | 08/01/2022 | Restricted Share Unit Award Vesting | TEVA PHARMACEUTICAL INDUSTRIES LIMITED | 52,744 | N | 08/03/2026 | Services Rendered |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
shares sold were pursuant to a sell to cover transaction from an established 10b51 plan adopted November 2025
Notice signature
- Notice date
- 08/03/2026
- Signed
- CONFORMED SIGNATURE ON FILE
- Plan adoption dates
- 11/10/2025
Company context
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health.
Current securities
Historical securities (1)
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 29, 2026
- 144 filingSep 21, 2026
- 144 filingSep 18, 2026
- Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet ArrangementSep 16, 2026
- Other EventsSep 14, 2026